-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Orna Therapeutics, a company dedicated to the development of circular RNA therapeutics, announced for the first time the preclinical proof-of-concept data of its flagship isCAR proje.
Circular RNAs are naturally occurring RNAs in mammals, and an important difference compared to linear RNAs is their stabili.
In addition, circular RNAs do not require the addition of a 5' cap and a 3' poly-A ta.
Moreover, compared with linear RNAs, circular RNAs have a more "compact" conformation produced by foldi.
▲The generation process of circular RNA of Oran company (Image source: Orna company official website)
Orna's flagship project is in situ CAR therapy (in situ CAR, isCAR), which uses LNPs to deliver circular RNAs to engineer immune cells in patien.
The company's press release noted that in mouse models, the company's oRNA-LNP complex was able to clear cancer cel.
The company also announced the first non-viral delivery method to deliver a circular RNA encoding full-length dystrophin into human cells and express dystroph.
Circular RNAs have attracted industry attention in recent years, and Laronde, a company founded by Flagship Pioneering last year, is also committed to developing circular RNA-based therapeuti.
References:
[1] Orna Therapeutics Announces First-in-Class, Breakthrough Data Demonstrating Potential of Circular RNA Platform at ASGCT 202 Retrieved May 17, 2022, from https:// 1
[2] Orna Proves Concept in Preclinical Oncology and DMD Mode.
